Clinic
Sentara Hospitals
Sentara Hospitals was paid $52.40M by Medicaid between Jan 2018 and Dec 2024, across 287 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
VIRGINIA BEACH, VA 23454
VIRGINIA BEACH, VA 23454
33aNPI1629038336assigned 03/25/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$52.40M
24GClaims1,393,125
24DCodes billed287
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#4 of 6
Median peer was paid$52.40M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 103,388 | $2.47M | |
| 2019 | 177,101 | $4.55M | |
| 2020 | 177,699 | $7.33M | |
| 2021 | 238,162 | $8.77M | |
| 2022 | 248,074 | $9.67M | |
| 2023 | 281,135 | $12.32M | |
| 2024incomplete | 167,566 | $7.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 61,485 | 51,902 | $10.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 47,428 | 38,501 | $7.81M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 21,947 | 16,196 | $6.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 27,737 | 22,600 | $4.77M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 18,702 | 16,459 | $2.89M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 12,176 | 10,637 | $2.32M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 12,559 | 10,547 | $2.27M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 2,199 | 1,920 | $1.17M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 22,181 | 5,930 | $1.12M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 3,224 | 2,850 | $813K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 1,298 | 1,136 | $780K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 5,813 | 5,020 | $695K |
275 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 3,382 | $615K |
| G0378 | Hospital observation service, per hour | 1.1% | 3,421 | $557K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 12,150 | $547K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.0% | 954 | $540K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,715 | $499K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,372 | $432K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,520 | $421K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,920 | $416K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 467 | $375K |
| 97161 | <1% | 3,819 | $355K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,863 | $319K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,763 | $312K |
| J3490 | Unclassified drugs | <1% | 218,455 | $305K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55,802 | $223K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 344 | $222K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,056 | $217K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,426 | $210K |
| 72141 | <1% | 990 | $190K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,254 | $176K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 908 | $174K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,050 | $168K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,687 | $157K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,573 | $148K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,130 | $146K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,009 | $142K |
| 93971 | <1% | 1,701 | $142K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 939 | $134K |
| 76830 | Ultrasound, transvaginal | <1% | 1,739 | $133K |
| 12001 | <1% | 648 | $131K | |
| 0240U | <1% | 2,125 | $130K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,266 | $124K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,514 | $123K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,534 | $112K |
| 10060 | <1% | 837 | $86K | |
| 70491 | <1% | 424 | $83K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,846 | $82K |
| 71250 | <1% | 1,252 | $79K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,337 | $77K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,001 | $77K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,829 | $75K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 961 | $71K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,896 | $70K |
| 70486 | <1% | 1,469 | $57K | |
| 74183 | <1% | 202 | $57K | |
| 80047 | <1% | 16,510 | $57K | |
| 93017 | <1% | 791 | $57K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 54,182 | $52K |
| 97162 | <1% | 578 | $47K | |
| 83880 | <1% | 5,515 | $45K | |
| 90715 | <1% | 2,285 | $44K | |
| 97165 | <1% | 836 | $42K | |
| 76642 | <1% | 321 | $38K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,299 | $36K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,893 | $36K |
| 76536 | <1% | 320 | $35K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,460 | $34K |
| 80076 | <1% | 19,444 | $34K | |
| 29125 | <1% | 300 | $32K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,326 | $32K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,654 | $30K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 740 | $30K |
| 97116 | <1% | 1,337 | $30K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,327 | $29K |
| 85379 | <1% | 6,187 | $29K | |
| 73221 | <1% | 137 | $28K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,416 | $27K |
| 80053 | Comprehensive metabolic panel | <1% | 5,409 | $27K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,733 | $27K |
| 85027 | <1% | 12,304 | $25K | |
| 84484 | <1% | 21,411 | $25K | |
| 73030 | <1% | 3,008 | $23K | |
| 93970 | <1% | 248 | $23K | |
| 73564 | <1% | 3,420 | $23K | |
| 12002 | <1% | 98 | $22K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 156 | $22K |
| 72110 | <1% | 1,204 | $22K | |
| 76770 | <1% | 163 | $21K | |
| 73630 | <1% | 3,326 | $20K | |
| 81025 | <1% | 17,452 | $20K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,131 | $19K |
| 87040 | <1% | 3,116 | $17K | |
| 82962 | <1% | 17,442 | $17K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 194 | $17K |
| 73130 | <1% | 2,679 | $15K | |
| 12011 | <1% | 66 | $15K | |
| 73502 | <1% | 1,720 | $15K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,537 | $14K |
| 94799 | <1% | 1,683 | $14K | |
| 77080 | <1% | 196 | $14K | |
| 84703 | <1% | 11,982 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,063 | $13K |
| 97016 | <1% | 428 | $13K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 65 | $12K |
| 71271 | <1% | 107 | $12K | |
| 93976 | <1% | 611 | $12K | |
| 73610 | <1% | 2,984 | $11K | |
| 85610 | <1% | 5,574 | $11K | |
| C1769 | Guide wire | <1% | 1,248 | $11K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 791 | $10K |
| 96376 | <1% | 9,063 | $10K | |
| 85014 | <1% | 9,028 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,227 | $9K |
| 73700 | <1% | 102 | $9K | |
| 72100 | <1% | 773 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,079 | $8K |
| 74018 | <1% | 786 | $8K | |
| 73110 | <1% | 1,563 | $7K | |
| 72146 | <1% | 43 | $7K | |
| 83735 | <1% | 5,927 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,253 | $7K |
| 81001 | <1% | 25,907 | $7K | |
| 83605 | <1% | 5,610 | $7K | |
| 80320 | <1% | 1,800 | $7K | |
| 86901 | <1% | 4,060 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,435 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,419 | $6K |
| 99234 | <1% | 202 | $6K | |
| 86900 | <1% | 4,057 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,122 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,075 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,821 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 116 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,603 | $5K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 587 | $5K |
| 73562 | <1% | 332 | $5K | |
| 83690 | <1% | 16,521 | $5K | |
| 76870 | <1% | 43 | $5K | |
| 86850 | <1% | 2,668 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 362 | $5K |
| 72050 | <1% | 199 | $5K | |
| 70544 | <1% | 17 | $5K | |
| 82565 | <1% | 2,470 | $4K | |
| 80061 | Lipid panel | <1% | 1,648 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 413 | $4K |
| 73560 | <1% | 312 | $4K | |
| 29515 | <1% | 14 | $4K | |
| 73140 | <1% | 790 | $3K | |
| 70496 | <1% | 14 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 97 | $3K |
| 81003 | <1% | 14,786 | $3K | |
| 85730 | <1% | 2,674 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,873 | $3K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 190 | $3K |
| 36000 | <1% | 62 | $3K | |
| 87210 | <1% | 6,621 | $3K | |
| 80143 | <1% | 568 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,434 | $3K |
| 84100 | <1% | 1,541 | $3K | |
| 82077 | <1% | 9,798 | $3K | |
| 87186 | <1% | 2,647 | $2K | |
| 73590 | <1% | 737 | $2K | |
| 87205 | <1% | 222 | $2K | |
| 88307 | <1% | 112 | $2K | |
| 73080 | <1% | 470 | $2K | |
| 84702 | <1% | 3,214 | $2K | |
| 87081 | <1% | 3,481 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,685 | $2K |
| 88342 | <1% | 2,351 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,171 | $2K |
| 82553 | <1% | 686 | $2K | |
| 90686 | <1% | 214 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,004 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,143 | $2K |
| C1729 | Catheter, drainage | <1% | 1,952 | $1K |
| 77336 | <1% | 25 | $1K | |
| 94729 | <1% | 57 | $1K | |
| 87077 | <1% | 3,886 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,309 | $1K |
| 80179 | <1% | 505 | $1K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 235 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,191 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,404 | $1K |
| 85018 | <1% | 693 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,161 | $1K |
| 94726 | <1% | 28 | $941.85 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,282 | $931.93 |
| 72120 | <1% | 24 | $888.34 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,840 | $886.42 |
| 96367 | <1% | 55 | $767.35 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,429 | $754.29 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,192 | $744.17 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,508 | $700.68 |
| 73090 | <1% | 282 | $608.48 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,409 | $608.32 |
| G0008 | Administration of influenza virus vaccine | <1% | 634 | $557.11 |
| 72170 | <1% | 186 | $522.38 | |
| 82310 | <1% | 3,453 | $520.90 | |
| 72072 | <1% | 48 | $504.18 | |
| 82550 | <1% | 1,284 | $484.29 | |
| 93880 | <1% | 21 | $460.28 | |
| 82330 | <1% | 171 | $459.22 | |
| 72040 | <1% | 50 | $458.11 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,813 | $432.41 |
| 93922 | <1% | 18 | $430.93 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 970 | $423.24 |
| 76801 | <1% | 18 | $421.02 | |
| 73660 | <1% | 44 | $411.48 | |
| 82607 | <1% | 64 | $399.01 | |
| 76937 | <1% | 28 | $383.10 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 392 | $322.50 |
| 83970 | <1% | 27 | $316.57 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,146 | $311.29 |
| 82803 | <1% | 592 | $309.18 | |
| 80164 | <1% | 70 | $296.37 | |
| 84439 | <1% | 48 | $284.74 | |
| 71101 | <1% | 42 | $270.62 | |
| 51798 | <1% | 20 | $257.30 | |
| 80329 | <1% | 14 | $229.01 | |
| 84145 | <1% | 48 | $227.68 | |
| 73552 | <1% | 62 | $190.81 | |
| 90688 | <1% | 88 | $146.87 | |
| 84132 | <1% | 138 | $141.23 | |
| 82746 | <1% | 32 | $135.77 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,075 | $135.42 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,116 | $131.86 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 143 | $131.52 |
| 90656 | <1% | 16 | $120.86 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 802 | $119.84 |
| 85652 | <1% | 133 | $113.38 | |
| 86140 | <1% | 48 | $111.47 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 349 | $98.16 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 190 | $92.76 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 594 | $90.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,665 | $87.90 |
| 82728 | <1% | 15 | $66.85 | |
| 83540 | <1% | 32 | $61.10 | |
| 82570 | <1% | 49 | $59.58 | |
| 36600 | <1% | 39 | $55.59 | |
| 83550 | <1% | 30 | $52.62 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 766 | $50.67 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 236 | $46.74 |
| 87070 | <1% | 185 | $44.85 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 305 | $44.18 |
| 82043 | <1% | 41 | $42.60 | |
| 88341 | <1% | 162 | $37.03 | |
| 90694 | <1% | 13 | $36.88 | |
| 88313 | <1% | 464 | $35.04 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 40 | $35.03 |
| 90653 | <1% | 105 | $28.82 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 239 | $27.42 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 246 | $23.74 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 43 | $21.86 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,062 | $18.47 |
| 87340 | <1% | 17 | $17.06 | |
| J1815 | Injection, insulin, per 5 units | <1% | 130 | $15.25 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 168 | $11.93 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 13 | $11.63 |
| 82272 | <1% | 40 | $11.56 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 66 | $8.21 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 205 | $7.16 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 90 | $6.89 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 140 | $3.02 |
| 90756 | <1% | 25 | $2.65 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 135 | $2.44 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 425 | $2.21 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18 | $2.06 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 222 | $1.88 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 15 | $1.79 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 326 | $0.76 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 414 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 145 | $0.00 |
| 82140 | 0% | 39 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 23 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 14 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 36 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 83 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 301 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 48 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 599 | $0.00 |
| 73060 | 0% | 12 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 163 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 15 | $0.00 |
| 88304 | 0% | 16 | $0.00 | |
| 90674 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.